Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-151P is a processed pseudogene related to the U6 small nuclear RNA (snRNA) family. U6 snRNAs are core components of spliceosomes and essential for pre-mRNA splicing[1][3]. Pseudogenes like RNU6-151P are formed through retrotransposition events and do not produce functional RNA or protein; they are generally considered non-functional and serve as genetic remnants or markers for genome evolution and transposable element activity[5]. While some pseudogenes participate in gene regulation or disease (often by acting as RNA sponges), there is no evidence that RNU6-151P fulfills such functions[2][4]. It is annotated in the human genome but has no known biological, pharmacological, or clinical relevance. Key points: - RNU6-151P is not a therapeutic target, enzyme, receptor, or biomarker. - It is a pseudogene, meaning it is a genomic sequence resembling a functional gene but lacking protein-coding or regulatory activity. - No drugs, mechanisms, or disease associations are documented for this specific pseudogene. - The entry is scientifically correct but not useful for therapeutic targeting purposes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 151, pseudogene (RNU6-151P).